Once-a-day stimulant is safe for ADHD, can be used after 1 year

Published Date: 13 Mar 2023

New research shows that once-daily speech-stimulating medications for the treatment of ADHD in people age 6 and older are safe and effective after one year of pain treatment.

Read Full News

Latest News

FDA OKs Drug to Treat Neurologic Symptoms in Hunter Syndrome

The U.S. Food and Drug Administration has approved Denali Therapeutics' therapy to treat children ⁠with a rare genetic disorder, marking the first regulatory green light for...

FDA Seeks New Warning for Certain Parkinson's Drugs

The FDA said on Friday it has notified manufacturers of certain Parkinson's ⁠disease treatments to update their prescribing information with a...

Scottish Lawmakers Vote Against Allowing Assisted Dying

Scottish lawmakers have voted against legalising assisted, crushing hopes for a historic law change, ⁠as similar proposals in England and Wales also look set to fail.

Little Evidence of Cannabis Efficacy for Psychiatric Illness

A new review shows insufficient or low-quality evidence to suggest cannabinoids are effective at treating most psychiatric conditions and substance use disorders.

Prenatal Antiseizure Med Exposure: Risks Vary by Agent

A large cohort study sheds new light on neurodevelopmental risk in children after prenatal antiseizure medication exposure, with variation across individual agents.

Anxiety and Depression May Raise Risk for Aneurysm Rupture

Anxiety and depression are linked to an increased risk for rupture and mortality in patients with unruptured intracranial aneurysms, a new cohort study shows.

Todays Updates

Novel Psychedelic Promising on Resistant Depression

An investigative inhaled formulation of the psychedelic mebufotenin is linked to significant improvements in depression symptoms compared to placebo, a phase 2b trial shows.

Biocomputer From Human Neurons Plays Doom, Raises Ethics

A biological computer using human neurons learns Doom within 1 week, highlighting rapid adaptive learning and potential advantages over traditional AI systems.

Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC

The findings could fill a treatment gap for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who also carry TP53 mutations.

EMA OKs Two Treatments for Small Cell Lung Cancer

Both drugs increase overall and progression-free survival.

Todays Updates

Novel Psychedelic Promising on Resistant Depression

An investigative inhaled formulation of the psychedelic mebufotenin is linked to significant improvements in depression symptoms compared to placebo, a phase 2b trial shows.

Biocomputer From Human Neurons Plays Doom, Raises Ethics

A biological computer using human neurons learns Doom within 1 week, highlighting rapid adaptive learning and potential advantages over traditional AI systems.

Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC

The findings could fill a treatment gap for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who also carry TP53 mutations.

EMA OKs Two Treatments for Small Cell Lung Cancer

Both drugs increase overall and progression-free survival.

Latest News

The U.S. Food and Drug Administration has approved Denali Therapeutics' therapy to treat children ⁠with a rare genetic disorder, marking the first regulatory green light for...

The FDA said on Friday it has notified manufacturers of certain Parkinson's ⁠disease treatments to update their prescribing information with a...

Scottish lawmakers have voted against legalising assisted, crushing hopes for a historic law change, ⁠as similar proposals in England and Wales also look set to fail.

A new review shows insufficient or low-quality evidence to suggest cannabinoids are effective at treating most psychiatric conditions and substance use disorders.

A large cohort study sheds new light on neurodevelopmental risk in children after prenatal antiseizure medication exposure, with variation across individual agents.

Anxiety and depression are linked to an increased risk for rupture and mortality in patients with unruptured intracranial aneurysms, a new cohort study shows.

News All Time

Positive Topline Results for Efgartigimod in Ocular MG

Efgartigimod led to statistically significant improvement in key symptoms of ocular myasthenia gravis compared with placebo in a phase 3 trial.

Smoking + Parkinson's: Lower Disease Risk, Higher Mortality

A large nationwide study revisits the smoking-Parkinson's paradox, linking current smoking to lower disease risk but linking quitting to lower all-cause mortality.

Stem Cell Therapy Safe, Feasible in Spina Bifida

A first-in-human trial shows the feasibility and safety of delivering placenta-derived stem cells during prenatal myelomeningocele repair.

Does Caring for Grandchildren Slow Cognitive Decline?

Grandmothers who care for grandchildren show slower cognitive decline over time than non-caregivers do.

Teen Cannabis Use Tied to Increase in Serious Mental Illness

A new study shows that teens with past-year cannabis use are twice as likely to be diagnosed with psychotic or bipolar disorders within 2 years of first use.

Fertility Treatments Linked to Higher Med Use in Offspring

Children conceived through medically assisted reproduction have higher out-of-hospital healthcare utilization including mental health medications.

Lifetime Risk Estimates for Dementia, MCI: New Data

Mild cognitive impairment before dementia is common in older adults, with women facing a higher lifetime burden and Black adults an earlier onset, new research shows.

Fibromyalgia-PTSD Link Shows Bidirectional Relationship

Research suggests a bidirectional relationship between posttraumatic stress disorder and fibromyalgia in military service members exposed to combat environments.

Redefining Cognitive Assessment With One Blood Test

Blood p-tau217 testing in real-world practice enhances diagnostic accuracy and neurologists' diagnostic confidence, with the greatest diagnostic shifts seen in mild cognitive impairment and dementia.

Trials Offer Mixed Results on BTK Potential for PPMS

Promising findings for fenebrutinib and disappointing results for tolebrutinib offer mixed results on the potential of BTK inhibitors for primary progressive MS.

Wrist-Worn Sleep Trackers Predict Depression Relapse

Actigraphy data show irregular sleep-wake rhythms nearly double the risk for relapse in individuals with remitted major depressive disorder.

What If We’ve Been Wrong About How ADHD Drugs Work?

A new analysis of brain scans from nearly 12,000 children could change the way clinicians and researchers think about how stimulants for ADHD work.

Vertebral Fractures Tied to Lower Lung Volumes in ILD

Thoracic vertebral fractures may worsen lung function and reduce lung volumes in patients with interstitial lung disease.

Japan Endorses IPS-derived Treatment for Parkinson's

A panel of specialists has endorsed an iPS cell-derived treatment for Parkinson's ⁠disease, paving the ‌way for the world's first medical products based on the technology.

Cognitive Training May Lower Dementia Risk 20 Years Later

In a long-running RCT, older adults who completed adaptive speed-of-processing training with boosters were less likely to develop dementia — a benefit not seen with memory or reasoning training.

Lifelong Cognitive Enrichment Tied to Lower Dementia Risk

Lifelong cognitive enrichment is linked to a lower risk for Alzheimer's disease, delayed onset, and better cognitive function despite brain pathology.

Recommended News For You

BMTs that are "half-matched" are effective in treating severe sickle cell disease.

Do I have prostate cancer? Why a simple PSA blood test alone won't give you the answer

Preventable pediatric cancer mortality surges in areas of armed conflict, exceeding rates in non-conflict regions

A hint regarding aspirin, the connection to colon cancer, the approval of the new Lutathera, artificial intelligence, and electronic records.

Obesity-associated cancers may be on the rise in Puerto Rico

combating racial discrimination in next-generation breast cancer screening.

Muscular strength and good physical fitness linked to lower risk of death in people with cancer

Recommended Articles For You

The Benefits and Risks of Transurethral Resection of Bladder Tumor  

Is p53 the Missing Puzzle Piece? Exploring Its Polymorphisms in Cervical Cancer Risk 

Unleashing the Power of Immune Triads: A Novel Approach to Cancer Immunotherapy 

The Truth About Marijuana and Its Effect on Mental Health  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Frontline Mosunetuzumab Shows High Response Rates in Follicular Lymphoma

2.

Novel Drugs Boost Immunotherapy Activity in Resectable Lung Cancer

3.

Higher Binge Drinking Rates Linked to New Cannabis Laws.

4.

Chemoradiation Plus Immunotherapy Fails to Improve Survival in Limited-Stage SCLC

5.

Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.

1.

The New Era of Oncology: Key Updates and Clinical Insights

2.

The Oncologist’s Edge: Tools, Trials, and Tech Transforming Treatment

3.

ctDNA in Aggressive B-Cell Lymphoma: Redefining MRD and Prognostic Monitoring

4.

The Immune Revolution: Neoantigen Vaccines and the Dawn of Personalized Cancer Therapy in 2025

5.

Epigenetics and Resistance: Mechanisms in Histone Methylation-Targeted Therapies

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI

2.

Optimizing Treatment Options in Advanced Urothelial Carcinoma

3.

Rates of CR/CRi and MRD Negativity in Iontuzumab-Treated Patients

4.

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session

5.

"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot